Amylyx Pharmaceuticals (AMLX) Q3 2024 earnings summary

Executive summary

• Advanced late-stage pipeline with focus on orphan neurodegenerative and endocrine diseases, highlighted by positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome and plans for Phase 3 avexitide in PBH in Q1 2025.

• Acquired avexitide, a GLP-1 receptor antagonist with FDA Breakthrough and Orphan Drug Designations; Phase 3 program in PBH to begin Q1 2025.

• Discontinued RELYVRIO/ALBRIOZA after negative Phase 3 PHOENIX trial results; no commercial products remain.

• Restructuring plan implemented in April 2024, reducing workforce by 70% and focusing resources on key clinical and preclinical programs.

• Ongoing development of AMX0035 for PSP (ORION trial) and AMX0114 for ALS, with interim and early cohort data expected in 2025.

Financial highlights

• Ended Q3 2024 with $234.4 million in cash, cash equivalents, and marketable securities.

• Net product revenue for Q3 2024 was $0.4 million, reflecting discontinued product sales and adjustments.

• Net loss for Q3 2024 was $72.7 million ($1.07 per share), compared to net income of $20.9 million in Q3 2023.

• R&D expenses decreased to $21.2 million (from $30.0 million YoY); SG&A expenses fell to $17.8 million (from $48.7 million YoY) due to restructuring and product discontinuation.

• $36.2 million expense recorded for avexitide acquisition as in-process R&D.

Outlook and guidance

• Cash runway expected to last into 2026, supporting key clinical data readouts.

• Phase 3 avexitide in PBH to initiate in Q1 2025; topline data expected in 2026.

• Interim data from Phase 2b/3 ORION trial of AMX0035 in PSP expected mid-2025; AMX0114 early cohort data in 2025.

• Combined R&D and SG&A spend (excluding stock-based compensation) projected at $30–$40 million per quarter in 2025.

• No expectation of near-term product revenue; future profitability dependent on successful development and commercialization of pipeline candidates.